Urs Meyer#

Activities

• 1981 - 1991 National Research Council, Swiss National Science Foundation
• 1988 - 1992 Advisory Board, Robert Bosch Stiftung, Stuttgart, Germany
• 1989 - 1991 President, Clinical Section, Division of Biology and Medicine, Swiss National Science Foundation
• 1989 - 1996 Member of the Board of Trustees, Sandoz Foundation for Gerontological Research, Basel.
• 1994 - 1998 Scientific Council, International Agency for Research on Cancer (IARC), WHO, Lyon, France
• 1997 - 2000 Swiss Board of Consultants, Basel Institute for Immunology
• 2000 - Co-editor Pharmacogenomics, Faculty 1000
• 2010 - 2011 President, International Society for the Study of Xenobiotics
• 2012 - 2015 President, European Center for Pharmaceutical Medicine Foundation

• Associate Editor, Annual Reviews of Pharmacology and Toxicology (2015- )
• Editor-in-Chief, Journal of Personalized Medicine ( 2011- 2014)
• Co-Editor “pharma-kritik”
• Co-Editor, Progress in Drug Research (1986 - 1988)
• Co-Editor, Advances in Drug Research (1993 - 1997)
  

• European Journal of Clinical Pharmacology (1985 - 2000)
• Clinical Pharmacology and Therapeutics (1986 - 1998)
• Thérapie (1990 - )
• Hepatology (1991 - 1997)
• Journal of Molecular Medicine (1994 - 2002)
• Pharmacogenetics & Genomics (1991 - )
• Molecular Diagnosis & Therapy (2000 - )
• Annual Review of Pharmacology & Toxicology (2005 -)
• Drug Metabolism and Drug Interactions , now Drug Metabolism and
• Personalized Therapy (2010 - )

• > 330; h-index 93, > 30’000 citations (Google Scholar 2018)

1. US Patent 07/845, 507 (Coinventor) "Method for identifying humans with genetic defects in drug metabolism"
   
2. US Patent Nr. 5,648,482 "Primers targeted to CYP2D6 gene for detecting poor metabolizers of drugs"

• BD-Biosciences, Woburn, USA

• Scientific advisor for various biotech and pharma companies
• Board of Directors, PharmaSens AG